Company management will also be participating in one-on-one meetings throughout the conference.
Key details about
Title of Presentation:
Presenter:
Date:
Time:
If you are interested in arranging a one-on-one meeting, please contact your conference representative or send an email to ir@ocuphire.com.
About
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders.
Ocuphire's lead retinal product candidate, APX3330, is an oral small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein) for the treatment of non-proliferative diabetic retinopathy (NPDR). Ref-1 is a regulator of the transcription factors HIF-1 and NF-B. Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of diabetic retinopathy (DR). A Phase 2 study in subjects with DR and an End-of-Phase 2 meeting have been completed, and a special protocol assessment (SPA) was submitted to the
In addition, Ocuphire has a partnership with
Ocuphire is also developing APX2009 and APX2014, second-generation analogs of APX3330. These programs are being evaluated for treating other retinal diseases such as age-related macular degeneration and geographic atrophy.
Contact:
Email: ir@ocuphire.com
Email: cdavis@lifesciadvisors.com
(C) 2024 Electronic News Publishing, source